It may be appropriate for individuals with weight-loss resistance, insulin resistance, metabolic syndrome, PCOS, elevated cardiometabolic risk, or those who were unable to tolerate full-dose GLP-1 therapy
These improvements correlated with reduced senescent cell burden in renal and hepatic tissue
Doctors note less common side effects that can be more serious, including pancreatitis and gallbladder problems
Backed by more than 80 years of science and medical data, these products have been selected for superior bioavailability and can help ensure a complete and personalized approach to meet your health goals.
Learn more about our Quality Promise
While the first new competitors to challenge Novo Nordisk and Lilly are not expected to enter the market until 2027, todays incumbents themselves face a near-term challenge of differentiation